Fagron continued strong turnover growth in first quarter 2019
April 12 2019 - 12:00AM
Regulated information
Nazareth (Belgium)/Rotterdam (The Netherlands), 12 April 2019 - 7am
CET
Fagron achieved turnover growth
of 13.1%
Key points
- Turnover increased by 13.1% to
€ 123.4 million
- Organic turnover growth of 7.1%
CER[1], mainly driven by strong growth in North and South
America
- Brands realized organic turnover
growth of 14.8% CER
- Further growth of turnover and
profitability expected in 2019
Rafael Padilla,
CEO of Fagron: "Fagron had an outstanding
start of 2019, with turnover growth of 13.1% and organic turnover
growth of 7.1%. The North America and South America segments
continued to perform very well, while the European segment's
turnover development, as previously announced, is still being
influenced by the temporarily reduction of the capacity at one of
our compounding facilities in the Netherlands. The compounding
activities at this facility were restarted in early April and we
expect the facility to be fully operational during the second half
of 2019. In contrast, Brands had a strong development in Europe,
partly driven by the successful start of Fagron Genomics.
In North America,
there was double-digit turnover growth in all activities. In
addition to strong turnover growth at the Wichita compounding
facilities, good progress was also made in the continued expansion
of the product range and the automation of the manufacturing
process. The sterile compounding facilities in Wichita are on track
to achieve the previously stated turnover target.
In South
America, Fagron managed to take advantage of
the continued positive market developments by ensuring good product
availability and further continued to differentiate itself through
the development and introduction of innovative Brands.
With our healthy
organic growth and disciplined acquisition strategy, we will
continue to expand our leading market positions in Europe, North
America and South America over the coming years. We see ample
opportunities in the market for personalized medicine, and I am
confident that our strategic focus puts us in a strong position to
seize those opportunities. This is supported by positive
developments in the first months of 2019, and we expect to continue
to grow further in turnover and profitability in 2019."
[1] CER =
Constant Exchange Rates.
Please open the link below for the
press release:
Fagron continued strong turnover
growth in first quarter 2019
This
announcement is distributed by West Corporation on behalf of West
Corporation clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Fagron NV via Globenewswire
Wt Agricultu Ld (LSE:FAGR)
Historical Stock Chart
From Nov 2024 to Dec 2024
Wt Agricultu Ld (LSE:FAGR)
Historical Stock Chart
From Dec 2023 to Dec 2024